Actopril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actopril

What is Actopril?

Actopril is a pharmaceutical medication belonging to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily utilized in the management of cardiovascular conditions, specifically focusing on the regulation of blood pressure and the reduction of strain on the heart.

Mechanism of Action

The medication works by inhibiting the activity of the angiotensin-converting enzyme. This enzyme is responsible for the conversion of angiotensin I into angiotensin II, a potent chemical in the body that causes blood vessels to tighten and narrow. By blocking this conversion, Actopril promotes the relaxation and widening of blood vessels, which facilitates easier blood flow and lowers systemic blood pressure.

Primary Uses

Actopril is commonly indicated for the following conditions:

  • Hypertension: It is used to manage high blood pressure, helping to prevent long-term complications such as strokes or heart attacks.
  • Heart Failure: It may be used to assist the heart in pumping blood more efficiently when the muscle has weakened.
  • Post-Myocardial Infarction: In certain cases, it is administered following a heart attack to improve survival rates and support cardiac function.
  • Diabetic Nephropathy: It is sometimes utilized to help protect kidney function in patients with diabetes who show signs of kidney disease.

Composition and Formulation

The active ingredient in this medication is captopril. It is typically formulated as an oral tablet and is designed to be absorbed rapidly into the bloodstream to begin its effect on the vascular system.

Regulatory References

  1. first-in-class oral ACE inhibitor (NIH)

What side effects are possible with Actopril?

Possible Side Effects and Safety Information: Actopril (Captopril)

The official safety profile for Actopril (Captopril), an ACE Inhibitor, details adverse reactions organized by incidence and affected physiological systems, as documented by government regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse effects are classified according to incidence based on regulatory documents:

Classification Examples of Documented Reactions
Very Common (ge 10%): Taste disturbance (Dysgeusia)
Common (ge 1% to <10%): Dizziness, persistent dry cough, rash, hypotension, nausea, vomiting
Uncommon (ge 0.1% to <1%): Tachycardia, chest pain, Angioedema
Very Rare (<0.01%): Neutropenia/Agranulocytosis, acute renal failure, hepatitis

System-Organ-Class Groupings

Documented reactions affect multiple body systems, including the Nervous System (dizziness, headache), Vascular and Cardiac Systems (hypotension, tachycardia), Respiratory System (cough), Gastrointestinal System, and Renal and Urinary System (proteinuria, impaired function).

Serious Safety Considerations

The regulatory label highlights certain reactions that, although rare, are considered serious. Angioedema, which involves swelling of the face, lips, or throat, is a critical safety concern documented in official sources. Severe Hypotension is also noted, particularly as a first-dose effect in volume-depleted patients. The medicine also carries a rare but serious risk of Blood and Lymphatic System Disorders, such as Neutropenia. Use during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of fetal injury and death.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on the official prescribing information for Captopril, the active ingredient in Actopril, as documented by regulatory authorities.

Immediate Emergency Action

Immediate medical attention must be sought if an overdose is suspected. Due to the risk of severe complications, the official regulatory guidance requires the patient to be kept under close medical supervision, preferably in an intensive care unit.

Documented Overdose Manifestations

Overdosage is primarily characterized by clinical signs resulting from excessively lowered blood pressure. The officially documented manifestations include:

  • Severe Hypotension (an extreme drop in blood pressure)
  • Shock (a critical state of insufficient blood flow)
  • Bradycardia (abnormally slow heart rate)
  • Stupor or Lethargy

Severe outcomes can include acute renal failure and significant electrolyte disturbances, which require continuous monitoring of serum creatinine and electrolytes.

Supportive Measures

There is no specific antidote listed in the official prescribing information for Captopril. Management is supportive and symptomatic, guided by regulatory protocols. These protocols include measures to prevent further absorption, such as gastric lavage or the administration of activated charcoal, and procedural steps for managing severe hypotension, such as rapid volume replacement and, if necessary, the use of agents like Angiotensin-II.

Therapeutic Uses of Actopril

What Actopril Treats: Main Uses and Benefits

Actopril (referring to Captopril) is commonly used to address conditions characterized by systemic imbalance and heightened physiological stress. This medication is applied in clinical settings that involve chronic systemic hypertension (high blood pressure), heart failure, and diabetic nephropathy (kidney damage in patients with diabetes).

The medicine is relevant for easing symptoms that interfere with daily functioning and supports the patient during difficult episodes. It is often used during phases when symptoms become more noticeable, such as fluid retention and shortness of breath (congestion) linked to heart weakness, and when supportive symptom management is appropriate for chronic blood pressure control.

“The primary goal is providing support that helps ease the overall symptom burden linked to chronic cardiovascular and kidney issues.”

This supportive treatment assists with maintaining functional stability and may contribute to reducing the risk of serious complications affecting the heart and blood vessels.


Quick Fact: Relief for Cardiovascular Strain

This medication is commonly used to help manage symptoms related to high pressure on the arteries and is considered relevant for easing the workload on the heart, particularly following a heart attack.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Actopril?

Eligibility for Actopril (Captopril) is strictly determined by official regulatory criteria, primarily related to patient history, physiologic state, and specific comorbidities.

Actopril is Contraindicated (Must Not Be Used) for:

  • Patients with a history of angioedema related to any prior ACE Inhibitor therapy, or with hereditary/idiopathic angioedema [Source 1.3, 1.8].
  • Pregnant patients during the second and third trimesters of pregnancy [Source 1.4, 1.8].
  • Patients with diabetes mellitus or renal impairment receiving aliskiren [Source 1.3, 1.8].
  • Use within 36 hours of taking a Neprilysin Inhibitor (e.g., Sacubitril/Valsartan) [Source 1.3].

Restricted or Conditional Use:

  • Pediatric patients (children and adolescents): Use is permitted but safety and efficacy are not fully established and require close medical supervision [Source 1.1, 1.8].
  • Impaired Renal Function: The initial dosage must be adjusted and reduced [Source 1.8].
  • Older Adults: A lower starting dose may be recommended due to the potential for reduced renal function [Source 1.8].
  • Pregnancy (First Trimester) and Lactation (especially newborns): Use is generally not recommended [Source 2.2, 2.6].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Actopril (Captopril) outlines restrictions and requirements based strictly on regulatory documentation.


Mandatory Contraindicated Combinations

Co-administration with Sacubitril/Valsartan is prohibited, requiring a 36-hour separation window when switching between the two to mitigate the risk of angioedema. The combination with Aliskiren is also prohibited in patients with diabetes mellitus or those with renal impairment (GFR less than 60 mL/min/1.73 m^2). Additionally, the strong CYP2D6 inhibitor Mavorixafor is a contraindicated combination as it increases Captopril plasma exposure.


Documented Pharmacodynamic and Pharmacokinetic Effects

Pharmacodynamic Interactions center on additive effects. Co-administration with potassium-sparing diuretics or potassium supplements increases the risk of hyperkalemia (high serum potassium levels). Other antihypertensive agents and alcohol may result in symptomatic hypotension due to additive blood pressure lowering. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are documented to reduce the blood pressure-lowering effect of Captopril and increase the risk of renal function deterioration.

Pharmacokinetic Interactions involve systemic exposure changes. Antacids and food reduce Captopril absorption; consequently, the medicine is officially taken one hour before meals. Captopril is also documented to reduce the renal clearance of Lithium, which can lead to increased serum lithium levels.

Mechanism of Action

Actopril (assumed to be Captopril, an ACE inhibitor) is a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), a zinc-containing metalloprotease primarily located on the luminal surface of endothelial cells, particularly in the pulmonary, renal, and systemic vasculature.

The primary biological target is the ACE enzyme. Actopril binds to the active site, preventing its catalytic function: the cleavage of the decapeptide Angiotensin I to the potent octapeptide Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS).

Inhibition of ACE results in a quantifiable decrease in circulating and tissue Angiotensin II concentration. This diminished Angiotensin II leads to reduced stimulation of the Angiotensin II Type 1 ( AT1) receptors on vascular smooth muscle cells, which promotes vasodilation and decreases total peripheral resistance. The reduced Angiotensin II signaling also lessens stimulation of the adrenal cortex, thereby decreasing aldosterone secretion. Reduced aldosterone action promotes urinary excretion of sodium and water, reducing extracellular fluid volume and circulatory volume.

Actopril also impedes the degradation of the potent vasodilator bradykinin, as ACE is identical to Kininase II. This increases localized bradykinin concentrations, further contributing to systemic vasodilation. The collective modulation of the RAAS and kinin-kallikrein system results in a reduction of both preload and afterload on the cardiac ventricles and a systemic reduction of arterial pressure.

Dosage and Administration Information

How Actopril is Used: Official Administration Guidelines

Actopril, containing the active ingredient Captopril, is administered orally via scored tablets. The use of this medicine is defined by specific procedural constraints and dosing regimens outlined in regulatory documents.


Administration Schedule and Context

Administration Scope Procedural Requirement
Route of Administration Oral (PO) is the standardized method
Dosing Frequency Typically administered two or three times daily, reflecting the drug's properties
Timing Relative to Meals Must be taken on an empty stomach, specifically one hour before a meal, as food intake significantly reduces compound absorption.

Labeled Dosing and Adjustment Rules

Official prescribing information details specific dosing ranges that depend on the condition being addressed.

  • Initial Doses: Therapy typically begins with a low dose, such as 6.25 mg or 12.5 mg, which is lower than the long-term maintenance dose. The standard starting regimen for hypertension is often 25 mg two to three times daily.
  • Maintenance Doses: Doses are gradually adjusted up to a typical maintenance range of 25 mg to 150 mg, with a maximum limit of 450 mg per day.

Titration and Special Populations: The dose must be increased slowly, generally with intervals of one to two weeks between adjustments, until the desired level is reached. For older adults and patients with renal impairment, the initial dose is explicitly required to be reduced, and titration intervals must be extended due to slower excretion of the drug.

Recent Clinical Evidence

Research evidence / Overview of studies for Actopril


Evidence for Use in High Blood Pressure (Chronic Systemic Hypertension)

The research into Actopril for high blood pressure is broadly categorized as High quality. This research structure includes numerous Randomized Controlled Trials (RCTs). These studies explored outcomes related to systemic or functional imbalance, primarily examining shifts in systolic and diastolic blood pressure and the incidence of major adverse cardiovascular events. Studies report how symptoms evolved in the observed populations. What remains unclear is research into different administration approaches for individuals whose high blood pressure is highly resistant to treatment. Comparative evidence is lacking in dedicated head-to-head trials against some of the newer, multi-drug combination therapies.


Evidence for Use in Easing Cardiac Strain (Heart Failure)

The evidence supporting the use of Actopril for managing heart failure is also categorized as High. The research relies on large, multi-center Randomized Controlled Trials (RCTs) that focused on long-term patient outcomes. Research examined outcomes reflecting daily functioning or activity level and outcomes related to physiological strain or stress, such as hospitalization rates. Trial reports described patterns where functional status metrics were observed in the research groups. However, comparative evidence is lacking for assessing outcomes observed with Actopril versus certain newer classes of heart failure medications.


Evidence for Use in Kidney Support (Diabetic Nephropathy)

The evidence for Actopril's role in supporting kidney health in individuals with diabetes is categorized as High. This research consists of Randomized Controlled Trials (RCTs) specifically designed to evaluate kidney protection. These studies monitored the progression of kidney disease, using the change in protein or albumin in the urine as the primary measurement. Findings describe patterns observed in the studies where research examined differences in the rate of increase of the measured biomarker for kidney disease progression compared to control groups.


Research Gaps and Limitations

The research base for Actopril is large, but some research limitations exist. The evidence base includes long-term outcome trials that tracked patients over several years, but long-term effects are not fully established for every measured parameter. Furthermore, while Actopril was evaluated in studies that included different cohorts of adults (such as post-heart attack patients), data for certain groups remain insufficient, particularly for advanced forms of the conditions or for highly specific comorbid populations. Research is ongoing to address these areas.

Key Studies & References

  1. Captopril: National Library of Medicine - MedlinePlus Drug Information
  2. Captopril: The First Angiotensin-Converting Enzyme Inhibitor

Frequently Asked Questions (FAQ)

Common questions about Actopril (FAQ)

Q: Can Actopril be taken long-term?

A: Studies and official information indicate that this medicine has been examined in long-term outcome trials for chronic conditions such as high blood pressure and heart failure. Regulatory documents do not typically specify an absolute time limit, as the use duration is subject to evaluation by a healthcare provider.

Q: Is it safe to take Actopril with common pain relievers?

A: Official labeling documents state that co-administering this medicine with certain common pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs), may reduce Actopril's blood pressure-lowering effect. This combination is also documented to increase the potential for kidney function issues.

Q: Is Actopril safe for use in older adults?

A: The official guidelines address use in older adults and state that the initial starting dose may be reduced. Dose adjustments are typically slower for this population due to the potential for reduced kidney function.

Q: Can people with kidney problems use Actopril?

A: For patients with impaired kidney function, regulatory documents require the initial dose to be adjusted and reduced. However, use is strictly prohibited when combined with the drug Aliskiren in patients who also have kidney impairment.

Q: Can Actopril be used while breastfeeding?

A: Use of the medicine during lactation is generally not recommended by regulatory agencies, especially when nursing newborns or premature infants. This information is found in official warnings and is based on a cautious approach to exposure.

Q: How is Actopril different from other similar medicines?

A: The active ingredient in Actopril is chemically distinguished in official documents by the presence of a sulfhydryl group. Furthermore, it is classified as not a prodrug, meaning the compound acts immediately upon absorption without requiring metabolic conversion to become active.

Q: Why do some patients need to get blood tests while using Actopril?

A: The regulatory label notes a rare but serious risk of Blood and Lymphatic System Disorders. This includes the potential for Neutropenia, which is a reduction in certain white blood cells. This risk is why monitoring of blood cell counts is included in official recommendations.

Q: Is Actopril an over-the-counter medicine?

A: No. Actopril is identified in all official sources as a prescription medication and is not available over the counter.

Q: Is Actopril a common cause of allergic reactions?

A: The most serious allergic-like reaction documented in the safety profile is Angioedema, which involves swelling of the face, lips, or throat. This event is classified as uncommon, meaning it affects less than 1% of patients in clinical trials.

Q: Are there specific food restrictions listed for Actopril?

A: Yes, official documents note the need to avoid salt substitutes containing potassium and potassium supplements. This is because the medicine can increase the levels of potassium in the blood, which can lead to elevated potassium blood levels, a known safety concern.

Q: What research is available on Actopril use in children?

A: Official documentation explicitly states that safety and effectiveness have not been fully established in pediatric patients, which includes children and adolescents. The regulatory status indicates a need for close medical supervision for any use in this population.

Q: Can Actopril be crushed or split?

A: Official guidelines caution against breaking, crushing, or chewing the tablet, even if it is scored. Patients are generally advised to follow the administration instructions specific to the exact product they receive.

Q: What are the typical results seen in clinical trials of Actopril?

A: Clinical trials typically examine the effects of the medicine through measurable outcomes. These outcomes include shifts in systolic and diastolic blood pressure, improvements in functional status metrics for heart failure, and the change in protein or albumin in the urine for diabetic kidney support.

Q: How quickly does Actopril usually start working?

A: According to official product information, the reductions of blood pressure are usually maximal 60 to 90 minutes after taking an individual dose of the medicine by mouth.

Q: How long do the effects of Actopril last after taking a dose?

A: The duration of the blood pressure-lowering effect is officially described as dose-related. This means that the length of time the medicine is active in the body depends on the specific amount taken.

Q: What happens if I miss a dose of Actopril?

A: Official guidance states that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the instruction is for the missed dose to be skipped to avoid taking a double dose.

Q: Do the side effects of Actopril go away over time?

A: For common, mild side effects like dizziness or changes in taste, official information notes that these effects may go away within a few days or a couple of weeks as the body adjusts to the medicine.

Q: Is it common to feel tired when starting Actopril?

A: Yes, official safety profiles list fatigue (excessive tiredness) as a common side effect. The incidence is generally categorized as being in the 1% to 10% range.

Q: Does Actopril cause weight gain or weight loss?

A: Weight gain is listed in official documentation as a symptom of potential serious side effects, specifically those related to kidney problems or fluid retention. It is not generally noted as a typical, stand-alone side effect.

Q: Can Actopril affect sleep?

A: Yes, the official safety profile includes sleep disorders and insomnia as documented side effects. These are typically listed within the psychiatric and nervous system categories.

Q: What if I already take a medicine for my condition; can Actopril be added?

A: Official prescribing information includes warnings about the potential for additive effects when Actopril is combined with other blood pressure-lowering agents. The risk of symptomatic hypotension (low blood pressure) is why official product information describes this situation as requiring careful evaluation.

Q: Has Actopril been approved in countries outside the U.S.?

A: The active ingredient, Captopril, has received regulatory approvals from governmental bodies in multiple regions globally, including the European Union (EU) and Australia (AU).

Q: How is Actopril cleared from the body?

A: According to the official pharmacokinetics, after the medicine is absorbed, it is primarily eliminated through the urine. A significant portion (approximately 40 to 50%) is eliminated as the unchanged drug.

Q: Do all people taking Actopril experience side effects?

A: No. Official patient materials state explicitly that not all patients who take this medicine will experience the documented side effects. The classification of side effects is based on the percentages observed in clinical trials.

Q: Is there a generic version of Actopril available?

A: Yes. The active ingredient, Captopril, was made available as a generic medicine in the U.S. in February 1996, according to official regulatory records.

Q: Does taking Actopril require changes to my diet?

A: Official guidelines note the need to avoid moderately high or high potassium dietary intake. This is an additional measure described to prevent the medicine from causing overly high potassium blood levels.

Q: What if I take too much Actopril by mistake?

A: If too much of the medicine is taken, a patient may experience a significant and severe drop in blood pressure. Official instructions state that if this occurs, emergency medical help must be sought immediately.

Q: How does Actopril affect the liver?

A: Official regulatory data notes that the active ingredient has been associated with a low rate of transient serum enzyme elevations. Rare instances of clinically apparent acute liver injury have also been documented.

Q: Is Actopril associated with mood changes?

A: The official safety profile lists depression and confusion as very rare side effects. These are typically categorized under the psychiatric and nervous system listings.

Q: Is Actopril a controlled substance?

A: No. Captopril, the active ingredient, is officially classified by regulatory authorities as Not a controlled medication.

How should Actopril be stored and disposed of?

Actopril (Captopril) storage and disposal instructions are governed by regulatory requirements to ensure product stability and patient safety.

Storage Requirements

Captopril tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture and must be kept away from direct light. The container must be kept tightly closed to maintain these environmental protections and preserve the tablet's integrity. It is an official requirement to Keep from freezing.

Child-Safety and Disposal

Mandatory labeling requires this medication to be kept out of the reach and sight of children, and the child-resistant cap must be secured after each use. Disposal of any unused, unwanted, or expired product must follow official local, regional, and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actopril found in:

A-Z Index: